Real-World Performance of the Artificial Intelligence-Enabled Electrocardiogram to Detect Increased Left Ventricular Filling Pressure to Predict Incidence of Heart Failure
Abstract Body (Do not enter title and authors here): Background: Our team recently developed an Artificial Intelligence model that enables the identification of increased left ventricular filling pressures using a single-lead electrocardiogram (AI-ECG) with excellent performance (AUC 0.91). However, its ability to predict incident heart failure (HF) in the community is yet to be evaluated. Hypothesis: We tested the hypothesis that the output from the AI-ECG will predict the long-term incidence of heart failure (HF) and HF with preserved ejection fraction (HFpEF), and would refine the HF predictive capabilities of the AHA Predicting Risk of Cardiovascular Disease EVENTs (PREVENTTM) Equations. Methods: Leveraging the resources of the Rochester Epidemiology Project (REP) we analyzed data from patients who sought primary care in Olmsted County, MN, between 1997-2003 with passive follow-up until April 2024. We included those with a digital ECG at baseline and excluded those who were part of the original algorithm development or history of heart failure. The diagnosis of heart failure was ascertained by using ICD codes (ICD9-428,ICD10-I.50) and a word search for the terms related to heart failure. HFpEF was ascertained using the Ejection Fraction (EF) data closest to the heart failure diagnosis date, using EF more than 40% as the criterion. We tested the association between AI-ECG predicted probabilities and new-onset HF and HFpEF using Cox proportional hazard models. These models were also adjusted for cardiovascular risk factors and were stratified to evaluate the effect of the AI-ECG output on PREVENTTM-predicted HF at 10 years. Results: We included 20,276 subjects, mean age 55±14.03, 52% women, 92% non-Hispanic white. After 18.2±8.5 years of follow-up, 4,008 (19.76%) were diagnosed with HF and 3,812 (18.8%) HFpEF. Risks of HF and HFpEF significantly increased in patients with increased left ventricular filling pressures by AI-ECG, independent of risk factors, all p for trend <0.001, see Fig A-B, respectively. AI-ECG enhanced the prediction capabilities of the PREVENTTM score across all risk groups, see Fig-C.
Conclusions: AI-ECG-Derived increased left ventricular filling pressure is associated with new-onset HF and HFpEF in the community and was associated with incidental heart failure at any PREVENTTM risk category. Those results suggest a potential role of AI ECG in predicting heart failure.
Bhyravajosyula, Sri Charan
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Medina-inojosa, Jose
( MAYO CLINIC
, Chicago
, Illinois
, United States
)
Medina-inojosa, Betsy
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Lee, Eunjung
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Mangold, Kathryn
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Friedman, Paul
( MAYO CLINIC
, Rochester
, Minnesota
, United States
)
Attia, Zachi
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Oh, Jae
( MAYO CLINIC
, Rochester
, Minnesota
, United States
)
Lopez-jimenez, Francisco
( MAYO CLINIC COLL MEDICINE
, Rochester
, Minnesota
, United States
)
Author Disclosures:
Sri Charan Bhyravajosyula:DO NOT have relevant financial relationships
| Jose Medina-Inojosa:DO NOT have relevant financial relationships
| Betsy Medina-Inojosa:DO NOT have relevant financial relationships
| Eunjung Lee:DO have relevant financial relationships
;
Royalties/Patent Beneficiary:Anumana:Active (exists now)
| Kathryn Mangold:DO NOT have relevant financial relationships
| Paul Friedman:DO NOT have relevant financial relationships
| Zachi Attia:DO have relevant financial relationships
;
Consultant:Anumana:Active (exists now)
; Consultant:Eko:Active (exists now)
; Consultant:AliveCor:Active (exists now)
; Ownership Interest:XAI.health:Active (exists now)
| Jae Oh:DO have relevant financial relationships
;
Royalties/Patent Beneficiary:Anumana:Active (exists now)
; Consultant:Medtronic:Active (exists now)
; Research Funding (PI or named investigator):REDNVIA:Active (exists now)
| Francisco Lopez-Jimenez:DO have relevant financial relationships
;
Employee:Mayo Clinic:Active (exists now)
; Advisor:Select Research:Active (exists now)
; Advisor:WizeCare:Active (exists now)
; Consultant:Kento Health:Active (exists now)
; Advisor:Novo Nordisk:Active (exists now)